Retatrutide, a dual GLP-1 and GIP receptor system agonist, is currently unavailable widely offered in the British Isles . While research are ongoing, approved launch dates remain uncertain . Patients interested in discovering more should consult their physician about possible options and be aware of further updates regarding its clearance . Reli… Read More